Background Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerability, alloreactivity, and efficacy of the administration of allogeneic memory T cells and natural killer (NK) cells in COVID-19 patients with lymphopenia and/or pneumonia. The aim of the study is to determine the safety and the efficacy of the recommended phase 2 dose (RP2D) of this treatment for patients with moderate/severe COVID-19. Methods In the phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of ≤ 2.5 liters per minute (lpm) in nasal cannula will be assigned to two arms, based on the biology of the donor and the patient. Treatment of arm A consists of the administration of escalating doses of memory T cells, plus standard of care (SoC). Treatment of arm B consists of the administration of escalating doses of NK cells, plus SoC. In the phase II trial, a total of 182 patients with COVID-19-related pneumonia and/or lymphopenia requiring or not oxygen supplementation but without mechanical ventilation will be allocated to arm A or B, considering HLA typing. Within each arm, they will be randomized in a 1:1 ratio. In arm A, patients will receive SoC or RP2D for memory T cells plus the SoC. In arm B, patients will receive SoC or RP2D for NK cells plus the SoC. Discussion We hypothesized that SARS-CoV-2-specific memory T-lymphocytes obtained from convalescent donors recovered from COVID-19 can be used as a passive cell immunotherapy to treat pneumonia and lymphopenia in moderate/severe patients. The lymphopenia induced by COVID-19 constitutes a therapeutic window that may facilitate donor engraftment and viral protection until recovery. Trial registration ClinicalTrials.gov NCT04578210 . First Posted : October 8, 2020 Supplementary Information The online version contains supplementary material available at 10.1186/s13063-021-05625-7.
【저자키워드】 COVID-19, protocol, Safety, Pneumonia, NK cells, lymphopenia, memory T cells, Allogeneic, 【초록키워드】 Treatment, Efficacy, clinical trial, Trial, Open-label, Study protocol, mechanical ventilation, Phase I, Pneumonia, T cells, Phase 2, Immunotherapy, NK cell, NK cells, oxygen, nasal, immune system, memory, lymphopenia, Randomized, T cell, Viral, Biology, memory T cells, Patient, HLA, convalescent, patients, memory T cell, Donor, administration, dose, COVID-19 patient, nasal cannula, therapeutic window, Standard of care, T-lymphocyte, natural killer, ARMS, Tolerability, Trial registration, supplementary material, treat, oxygen supplementation, Oxygen requirement, SOC, memory T, alloreactivity, T cell lymphopenia, Cell, evaluate, the patient, facilitate, can be used, determine, assigned, dysregulated, receive, 1:1, 【제목키워드】 therapy, Coronavirus pneumonia, Pneumonia, memory T cells, memory T cell, natural killer cell, dose-escalation, evaluate,